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ABSTRACT 275 
Recent increasing evidence supports a role for neuronal type signaling in bone. Specifically glutamate 
receptors have been found in cells responsible for bone remodeling, namely the osteoblasts and the 
osteoclasts. While most studies have focused on ionotropic glutamate receptors, the relevance of the 
metabotropic glutamate signaling in bone is poorly understood. Specifically type 1 metabotropic 
glutamate (mGlu1) receptors are expressed in bone, but the effect of its ablation on skeletal 
development has never been investigated. Here we report that Grm1crv4/crv4 mice, homozygous for an 
inactivating mutation of the mGlu1 receptor, and mainly characterized by ataxia and renal 
dysfunction, exhibit decreased body weight, bone length and bone mineral density compared to wild 
type (WT) animals. Blood analyses of the affected mice demonstrate the absence of changes in 
circulating factors, such as vitamin D and PTH, suggesting renal damage is not the main culprit of 
the skeletal phenotype. Cultures of osteoblasts lacking functional mGlu1 receptors exhibit less 
homogeneous collagen deposition than WT cells, and present increased expression of osteocalcin, a 
marker of osteoblast maturation. These data suggest that the skeletal damage is directly linked to the 
absence of the receptor, which in turn leads to osteoblasts dysfunction and earlier maturation. 
Accordingly, skeletal histomorphology of Grm1crv4/crv4 mice suggests that the absence of the 
mGlu1 receptor causes enhanced bone maturation, resulting in premature fusion of the growth plate and 
shortened long bones, and further slowdown of bone apposition rate compared to the WT mice. 
In summary, this work reveals novel functions of mGlu1 receptors in the bone and indicates that in 
osteoblasts mGlu1 receptors are necessary for production of normal bone matrix, longitudinal bone 
growth, and normal skeletal development. 
 
Key words: mGlu1 receptor, Grm1crv4 mouse, bone mineralization, skeletal defect, ataxia, SCAR13  
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1. Introduction 
The metabotropic glutamate (mGlu) receptors belong to family C G-protein coupled receptors. mGlu 
receptors are a heterogeneous subfamily with different subtypes and are divided into three groups 
based on sequence homology and signal transduction pathways. Group I consists of the mGlu1 and 
mGlu5 receptors, coded by the Grm1 and the Grm5 genes, respectively. mGlu1 receptor is primarily 
coupled to Gq/G11 protein and its activation stimulates phospholipase C β (PLC β) with the ensuing 
formation of the intracellular second messengers, inositol-1,4,5-trisphosphate (Ins-1,4,5-P3) and 
diacylglycerol (DAG) (reviewed in [1]). In turn, Ins-1,4,5-P3 production leads to the release of Ca2+ 
from intracellular stores, whereas DAG activates protein kinase C. The mGlu1 receptor is present in 
a number of key central nervous system (CNS) structures including the hippocampus, cortex, 
thalamus and cerebellum [2]. The receptor plays an important role in neuronal cells by triggering 
various signaling pathways that modulate neuron excitability, synaptic plasticity, and mechanisms of 
feedback regulation of neurotransmitter release [1, 3]. mGlu1 receptor is also expressed in non-
neuronal tissues, e.g. skin, pancreas, liver, heart, retina and bone [4-9]. In the kidney, mGlu1 receptors 
are present particularly in glomerular podocytes, where they play an important role in podocyte 
signaling and glomerular intercellular communication [8, 10]. 
The implication of the glutamate signaling pathways in bone mass regulation has been studied 
extensively during the past years. Accumulating evidence supports the expression in bone cells of all 
functional elements of glutamate signaling [11-15], particularly in cells responsible for bone 
remodeling, such as osteoblasts and osteoclasts. In addition, osteoblasts have been found to be able 
to release and recycle glutamate using mechanisms identical to those of neuronal cells [16, 17]. 
Finally, functional mGlu1 receptor has been detected in primary culture of rat femoral osteoblasts, as 
demonstrated by the fact that its activation leads to an elevation of intracellular Ca2+ levels [4]. 
We previously described a mouse carrying a spontaneous recessive mutation in the Grm1 gene 
(crv4)[18]. The crv4 germline mutation affects constitutively all tissues and gives rise to a complex 
phenotype, mainly characterized by ataxia and tremor due to impaired cerebellar activities, renal 
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dysfunction, and kyphoscoliosis particularly evident in female mice [8, 18, 19]. 
As for the skeletal phenotype, it could be an indirect consequence of neuronal and renal changes, or 
it can be directly caused by Grm1 expression absence in bone cells. 
Based on the evidence that mGlu receptors are expressed in bone, we hypothesized that absence of 
Grm1 expression from osteoblasts could lead to impaired glutamate signaling and consequently to 
pathological changes in bone remodelling. Therefore, the aim of the current study was to conduct a 
detailed analysis of the skeletal phenotype of the Grm1crv4 mice. To determine the impact of mGlu1 
receptors absence on the skeletal phenotype in vivo, we analysed body weights and lengths of affected 
and wild type animals, and carried out bone histomorphology and blood biochemical analyses. The 
direct effects of constitutive Grm1 from osteoblasts were determined in vitro, in osteoblasts isolated 
from mice lacking Grm1, and from wild-type control animals. The results suggest that absence of 
mGlu1 receptor from osteoblasts directly contributes to the skeletal abnormalities present in 
Grm1crv4/crv4 mice. 
 
2. Materials and methods 
2.1 Animal model and ethics statement 
The crv4 mutation is a spontaneous recessive mutation occurred in the BALB/c/Pas inbred strain that 
disrupts the Grm1 splicing and causes absence of the mGlu1 receptor protein [18]. Affected 
(Grm1crv4/crv4) and control (Grm1+/+) mice are maintained on the same genetic background by 
intercrossing Grm1crv4/+ mice at the animal facility of the IRCCS San Martino-IST (Genoa, Italy). 
Mice are given free access to water. Normal chow food is placed on the floor to ensure that all mice 
are fed in equal measure. To obtain the genotype of the mouse progeny, DNA was extracted from ear 
clippings according to the manufacturer's protocol (KAPA Mouse Genotyping Kits, Kapa 
Biosystems, Woburn, MA, USA) and amplified via polymerase chain reaction (PCR) using specific 
primers as previously described [20]. In this study a total of 52 Grm1crv4/crv4, 42 Grm1crv4/+, and 52 
Grm1+/+ (WT) mice were used, with an equal number of females and males per genotype. 
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All procedures involving animals were performed in the respect of the National and International 
current regulations (D.lvo 27/01/1992, n° 116, European Economic Community Council Directive 
86/609, OJL 358, Dec. 1, 1987) and were reviewed and approved by the licensing and Ethical 
Committee of the IRCCS-AOU San Martino-IST National Cancer Research Institute, Genoa, Italy, 
and by the Italian Ministry of Health. 
2.2 Mouse body weight and body length measurements 
Body weights and lengths of 10 males and 10 females WT and Grm1crv4/crv4 were measured at 24 
weeks of age. Body length was determined by measuring nasal-to-anal distance using a caliper 
immediately after the mice were killed before organ collection. 
2.3 X-ray analysis, imaging techniques and image processing 
Hind limbs of 12 to 28 weeks old sex- and genotype- matched mice were analysed. Mouse hind limbs 
were X-rayed and bone length and density were measured using the Bruker In-Vivo FX PRO imaging 
system (Foley et al, application note, in preparation and [21]). Briefly, the X-ray energy was 
calibrated to 12.85 – 13.03 Kev, thus the X-ray quantum efficiency is maximal at energy levels 
between 10 and 15 Kev [22]. Imaging and image processing were performed via Carestream (Bruker) 
Molecular Imaging Software v5.0.2. The software interface enables estimation of bone mineral 
density in a certain region of interest (ROI) selected by the user from the X-ray image [22]. The X-
ray images were processed with the Carestream software, rotated and mirrored, so that the femoral 
axis was as horizontal as possible and the images had the same orientation (the condyle on the left 
hand side and the femoral head on the right hand side). A standard size ROI was selected in the most 
cylindrical region of the bone. Bone length and surface density were calculated with the same tool. 
Femur length was measured by drawing a straight horizontal line from the most exterior point of the 
femoral head, to the most exterior point of the condylar extremity. The tibia was measured in a 
comparable manner. 
2.4 Bone histomorphometry 
Histomorphology of the hind limbs of 12 and 24 weeks old mice (N = 3 per genotype) was analysed 
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by hematoxylin and eosin (H&E) staining. The femora were isolated and immersed in 342 mM 
EDTA, 7.2 pH for 21 days. Following demineralization, the tissue was paraffin-embedded and 5 µm 
thick sections were mounted on Plysine microscope slides. Sections were subjected to H&E staining 
and toluidine blue staining, performed with an R.A. LAMB Histomate and the slides were mounted 
with DPX. 
2.5 Histomorphometric analysis of bone formation 
To assess bone formation indices, mice received two intra-peritoneal injections of calcein (10 mg/kg 
dissolved in 2% Na2HCO3 in PBS) (Sigma Chemical Company, St. Louis, USA) 14 and 3 days before 
sacrifice. Calcein double labelling was quantified in methylmethacrylate embedded sections. Femora 
from WT and Grm1crv4/crv4 mice were recovered and infiltrated with the light-curing resin Technovit 
7200VLC (Kulzer, Wehrheim, Germany) for 21 days under vacuum with resin replaced every 7 days. 
Samples were polymerized by the EXAKT 520 polymerization system (EXAKT Wehrheim, Bio-
Optica, Italy) with curing performed with 450 nm light at temperature bellow 40°C. The specimens 
were then prepared to be cut, according to the precision paralleling-guide procedure protocol, using 
the precision presses Exakt 401 and 402 Vacuum Adhesive Press (EXAKT Wehrheim, Bio-Optica, 
Italy). Sections were cut using the EXAKT 310 CP cutting unit (EXAKT Wehrheim, Bio-Optica, 
Italy). Obtained sections were approximately of 150 µm in thickness. Sections were then grinded to 
20–30 µm thickness using the EXAKT 400 CS micro grinding unit (EXAKT Wehrheim, Bio-Optica, 
Italy). Sections were stained with Stevenel’s/Van Gieson. For all processed samples, images were 
taken using Axiovert 200M microscope (Zeiss, Germany) [23]. Mineralizing surface (MS) and 
mineral apposition rate (MAR, μm/d) were measured from unstained sections, and bone formation 
rate was calculated (BFR=MS/BS ∗ MAR, μm2/μm3/d)[24]. 
2.6 Immunohistochemistry and immunocytochemistry 
For immunohistochemistry (IHC), tibia recovered from 4 weeks old Grm1crv4/crv4 and WT mice were 
fixed in 4% formaldehyde/phosphate-buffered saline. Paraffin-embedded sections were decalcified 
(HCl 37% / Formic acid 85% /distilled water), dewaxed and incubated with the following primary 
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antibodies: rabbit anti-mGlu1 receptor, NB300-123 NOVUS; rabbit anti-collagen I, ab292 ABCAM. 
Then IHC was performed using super picture HRP polymer conjugated broad spectrum detection kit 
(Invitrogen), diaminobenzidine (DAKO). Sections were counterstained with Brilliant cresyl blue 
(BCB). Then IHC was performed using super picture HRP polymer conjugated broad spectrum 
detection kit (Invitrogen), diaminobenzidine (DAKO). Sections were counterstained with Brilliant 
cresyl blue (BCB). Double immunofluorescence staining was performed using mouse femur frozen 
tissue sections fixed in cold acetone. In brief, after blocking with BSA 1%, the tissue was incubated 
with the primary antibodies as follows: mouse anti-RUNX2 (Abcam), rabbit anti-mGlu1 receptor, 
(Novus Biologicals), and rat anti-CD68 (Serotec), followed by fluorescently labeled secondary 
antibodies Alexa Fluor 488 donkey anti-rabbit IgG, Alexa Fluor 488 goat anti-mouse IgG, Alexa 
Fluor 546 goat anti-mouse IgG, and Alexa Fluor 546 anti- rat IgG (Molecular Probes). For osteoblasts 
and osteoclasts count, experiments were conducted on 3 mice replicates WT and Grm1crv4/crv4, taking 
2 bone diaphysis and 2 epiphysis for each condition, and using 10 ROIs for each image. 
For immunocytochemistry, the cells fixed in acetone were incubated with the primary antibody, a 
rabbit anti-collagen I (ab292 ABCAM), and Alexa Fluor 546 goat anti-rabbit IgG highly cross 
adsorbed (Invitrogen) as a secondary rhodamine-labelled antibody. 
Images were acquired using a Zeiss Axioscope 40FL microscope, equipped with AxioCam MRc5 
digital videocamera and immunofluorescence apparatus and AxioVision software 4.3 (Carl Zeiss 
SpA, Arese, Mi, Italy). 
2.7 ALP and TRACP staining 
The activity staining of alkaline phosphatase (ALP) and tartrate-resistant acid phosphatase (TRACP) 
was carried out separately on mouse femur frozen tissue sections using a commercially available kit 
(Takara Bio) in which chromogenic substrates for alkaline phosphatase, an enzyme marker of 
osteoblasts, and tartrate-resistant acid phosphatase, an enzyme marker of osteoclasts, are used. 
Briefly, after fixation with 45% citrate buffer and 10% acetone, the enzyme substrates were added on 
separate slides and incubated at 37°C.  
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2.8 Blood and Serum Biochemistry 
Blood samples were obtained from each mouse through retro-orbital veins. Baseline serum 
parameters were evaluated in 20 weeks old WT and Grm1crv4/crv4 mice. Murine C-terminal 
telopeptides of collagen type I (CTX-I) were determined in serum by using the commercial kit Ratlaps 
EIA (Immunodiagnostic systems Ltd, Frankfurt am Maim, Germany). 1,25-Dihydroxy Vitamin D 
was purified and determined in serum by using the IDS 1,25-Dihydroxy Vitamin D 
(Immunodiagnostic systems Ltd) commercial kit. Parathyroid hormone (PTH) was measured by the 
Mouse PTH 1-84 ELISA Kit (Immutopics, San Clemente, CA, USA). Calcium and phosphate were 
determined in plasma by using a COBAS C600 (Roche, Milan, Italy) analyzer. 
2.9 Osteoblast cultures and treatments 
Primary osteoblasts were isolated from 4 weeks old mice of the three genotypes (WT, Grm1crv4/+ and 
Grm1crv4/crv4), according to a well-established procedure [25]. Briefly, calvaria were removed, parietal 
bones were cut in two halves, and subjected to four sequential digestion steps (15 min each, at 37 °C) 
in PBS with 0.05 % CollagenaseP (Roche) and 0.1 % Trypsin (Thermo Fisher Scientific, MA, USA). 
Cells from the first digestion were discarded, cells from the 2nd to the 4th digestion were placed in 
alpha-MEM medium (Thermo Fisher Scientific) supplemented with 10 % FBS and 1 % 
streptomycin/penicillin, 50 μg/mL ascorbic acid and 3 mM glycerol 2-phosphate disodium salt 
hydrate (Sigma- Aldrich, Milan, Italy). After 24 h medium was changed, thereafter, medium was 
changed every other day. When cells reached confluence, they were trypsinised and seeded at a 
density of 10,000 cells/cm2 to get second passage cells. Cells were monitored daily to assess 
morphology, and experiments performed after 10 days of cultures. Notably, mGlu1 receptor 
expression is retained by WT cells (RT–PCR method described in the Supporting information and 
results shown in Supplementary figure 4). Cell viability was assessed by Trypan blue uptake (Trypan 
Blue Solution, Sigma-Aldrich) in three wells per genotype after 24, 48 and 72 hours after plating. In 
order to assess DNA synthesis and cell proliferation, BrdU incorporation was measured using the 
BrdU cell Proliferation assay kit (Cell Signaling Technology, Danvers, Massachusetts, USA) 
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according to the manufacturer's instructions. Twenty-four hours after plating, BrdU reagent was 
added to the wells and incubated for 24 h, 48 h or 72 h. Three wells per genotype per time point were 
analysed. 
Pharmacological inhibition of mGlu1 receptors in osteoblasts was also performed. Osteoblasts 
isolated from WT animals were treated with 7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxylate 
ethyl ester (CPCCOEt)(Hello-bio, Portishead, Bristol, UK), a known selective mGlu1 receptor 
antagonist [20], at a final concentration of 10 μM in 0.01% DMSO or with vehicle (DMSO 0.01%) 
only. Treatment was repeated on alternate days for a total of 10 days, when osteoblasts reached 
confluence. All experiments were performed in triplicate. 
2.10 Real-time Quantitative Reverse Transcriptase-Polymerase Chain Reaction (qRT-PCR) assay 
Total RNA was extracted using Trizol (Invitrogen) from osteoblasts kept in culture for 10 days, as 
described above. cDNA was prepared from 3µg RNA using the iScript Select cDNA Synthesis Kit 
and oligo(dt)20 primers (Bio-Rad, Segrate, Milan, Italy). Gene expression levels were quantified 
using gene-specific primers (Supplementary file). Real Time RT-PCR was run with iQ Sybr Green 
Supermix (Bio-Rad) on a MyIQ instrument (Bio-Rad) and data were analysed by the IQ5 Bio-Rad 
Software. 
The relative expression levels of mRNA from Grm1crv4/crv4 osteoblast cells were calculated using the 
ΔΔCt method [26] normalizing to Gapdh and relative to WT cells. Three replica per mouse, and three 
mice per genotype were analysed. 
Analogously, the relative expression levels of mRNA from CPCCOEt treated osteoblast cells were 
obtained using the ΔΔCt method [26] normalizing to Gapdh and relative to DMSO treated cells. 
2.11 Alizarin red staining and extraction methods 
Alizarin red staining solution (1 mg/mL, pH 5.5, Sigma-Aldrich) was added to ethanol-fixed 
osteoblasts then cells were destained by 5% perchloric acid. Optical density of the supernatant was 
evaluated by spectrophotometry at 450 nm. To normalize, Yanus Green Whole-cell Stain was added 
for 10min followed by Elution buffer and absorbance was read at 615nm. All experiments were 
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carried out using 3 replicates per each treatment. 
2.12 ALP activity 
To evaluate ALP activity in cultured cells, the medium was removed, the wells rinsed once with PBS, 
and 0.2 ml p-nitrophenyl phosphate (pNPP) (Sigma-Aldrich) was added to the wells and incubated 
for 30 seconds at room temperature in the dark. The reaction was stopped by the addition of 3 N 
NaOH and the sample was analyzed at 405 nm by the GloMax-Multi Detection System (Promega, 
Madison, WI, USA). The amount of protein was determined using a Pierce BCA Protein Assay kit 
(Thermo-Fischer Scientific), and the absorbance was read at 560 nm with the GloMax-Multi 
Detection System. ALP activity was defined by dividing the values from the pNPP assay by the values 
from BCA total protein to represent normalized alkaline phosphatase activity per unit total protein. 
2.13 Sirius Red staining 
Osteoblast cells were fixed in 4 % paraformaldehyde, then Sirius red solution (Polysciences, inc, 
Warrington, PA, USA) was added and washed with tap water after 1 hour incubation. Cells were 
destained by NaOH 0.1M. Optical density of the supernatant was evaluated by spectrophotometry at 
540 nm wavelength. To normalize, Yanus Green Whole-cell Stain (Fisher Scientific, Rodano Milan, 
Italy) was added for 10min followed by Elution buffer and absorbance was read at 595 nm. All 
experiments were carried out using 3 replicates per each mouse, and three mice per genotype. 
2.14 Statistics 
Analysis of variance (ANOVA) was used for continuous, normally-distributed variables; Tukey post-
hoc test was used to determine significance between multiple groups. Comparisons between two 
groups were carried out using an unpaired, two-tailed Student’s t test. The Kruskal Wallis 
nonparametric test was used when the normality assumption was violated, in which case the 
Wilcoxon-Mann-Whitney test was used for pairwise comparisons. Between subjects t-test using 
Levine’s test for equality of variances was used to assess differences in bone parameters. For all 
statistical analyses, a p-value less than 0.05 was considered to be statistically significant. 
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3. Results 
3.1 Grm1crv4/crv4 mice exhibit impaired skeletal development in vivo compared to WT animals 
The body weight of homozygous mutant mice was reduced with respect to that of WT mice of about 
25%. Analogously, body length of Grm1crv4/crv4 mice was about 10% shorter than that of WT mice. 
Heterozygous Grm1crv4/+ did not exhibit any differences in weight or length compared to that of WT 
animals (Figure 1 A-C, Supplementary table 1 and Supplementary table 2). 
Analysis performed on sex-matched WT, Grm1crv4/+ and Grm1crv4/crv4 mice of pooled ages (12 – 28 
weeks) showed a statistically significant decrease of femoral length both in female and in male 
Grm1crv4/crv4 mice when compared to WT females and males (Figure 1D). Femur length of 
Grm1crv4/crv4 female and male mice was shorter also with respect to heterozygous Grm1crv4/+ female 
and male counterparts (Figure 1D). Tibial length of the homozygous mutant female and male mice 
was shorter than that of WT females and WT males, respectively, the difference being statistically 
significant only in female animals (Figure 1D). Femoral length and tibia length of heterozygous 
Grm1crv4/+ mice did not differ statistically from those of WT animals. Indeed, anterior-posterior 
femoral width was reduced in female and not in male Grm1crv4/crv4 mice relative to heterozygous and 
WT animals (Supplementary Figure 1A, 1B). 
Bone mineral density of male Grm1crv4/crv4 mice showed a statistically significant reduction when 
compared to WT and Grm1crv4/+ mice (Figure 1E). Similarly, bone surface density of male 
Grm1crv4/crv4 mice was significantly reduced with respect to that of WT and of Grm1crv4/+ mice (Figure 
1E). In the female animals no difference in bone mineral density and bone surface density could be 
detected when mice of pooled ages (12 – 28 weeks) were analysed (Supplementary Figure 1C, 1D). 
When only animals of 24 weeks of age were considered, a statistically significant reduction in bone 
mineral density of female Grm1crv4/crv4 with respect to WT mice and, accordingly, bone surface 
density in Grm1crv4/crv4 with respect to WT mice was observed (Figure 1E). There was no statistically 
significant difference of either bone mineral density or surface density between heterozygous 
Grm1crv4/+ and WT mice (not shown). 
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Levine’s test for equality of variances showed no statistically significant difference in tibia length 
(mm) (t(4) = 2.026, p = 0.113), bone mineral density (g/cm3) (t(4) = 0.961, p = 0.391) and bone 
surface density (g/cm2) (t(3) = 1.744, p = 180) of WT male mice of 12 and 20 weeks age. Similarly, 
no statistically significant difference was detected in tibia length (mm) (t(4) = 0.210, p = 0.844), bone 
mineral density (g/cm3) (t(4) = 1.273, p = 0.272) and bone surface density (g/cm2) (t(4) = 1.626, p = 
0.179) of WT female mice of 12 and 24 weeks old. 
All together, these observations indicate growth retardation and bone mineralization defects in 
Grm1crv4/crv4 mice, which were not present in heterozygous Grm1crv4/+ animals. 
 
H&E staining of the hind limbs of 12 weeks old WT mice (Supplementary Figure 2A-C) and 
Grm1crv4/crv4 mice (Supplementary Figure 2D-F) showed that the growth plate in the distal epiphysis 
of the femora was active at this age. However, when observing the 24 weeks old Grm1crv4/crv4 mice 
(Figure 2A and Supplementary Figure 2J-L), it was noted that the process by which chondrocytes are 
embedded into calcified matrix was completed and thereby the growth plate transformed into 
epiphyseal line, whereas in the 24 weeks WT mice epiphysis (Figure 2A and Supplementary Figure 
2G-I) secondary ossification centers were still present, osteoblasts were still invading the cartilage 
matrix, causing ossification, indicating that the epiphyseal line has not yet fused. Thus, longitudinal 
bone growth is still an on-going process in 24 weeks old WT mice, while in the 24 weeks old 
Grm1crv4/crv4 mice the growth plate fused, ceasing the longitudinal bone growth. Overall, these data 
suggest that bone growth terminates earlier in the Grm1crv4/crv4 than in the WT mice. 
We wondered if this observation was associated to an imbalance in the number of 
osteoblasts/osteoclasts in the mutated bone tissues. By using enzymatic histochemistry we evaluated 
the presence of ALP-positive osteoblasts and TRACP-positive osteoclasts at bone epiphysis of WT 
and Grm1crv4/crv4 mice. This double staining analysis did not reveal any difference in number and/or 
distribution of osteoblasts and osteoclasts in the mutated with respect to the WT tissues (Figure 2B).  
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Indeed, we performed double immunofluorescence analyses with antibodies specific for Runx2, as 
marker for osteoblasts, and the mGlu1 receptor in diaphysis (Figure 3A-C). As expected, Runx2 and 
mGluR1 double positive cells were clearly observable in the wild type tissues and absent in the 
mutated bone. To note, no difference in the number of osteoblasts (Runx2-positive cells) was 
observable between mutated and wild type tissues. We than analysed bone epiphysis of WT and 
mutated mice by double immunofluorescence using antibodies specific for the osteoclast marker, 
CD68, and for the mGlu1 receptor (Figure 2D-G). No difference in the number of osteoclasts (CD68-
positive cells) was observable between mutated and wild type tissues. Of note, a few CD68-
expressing osteoclasts also expressed mGlu1 receptors (Figure 2E). 
We next carried out histomorphometry on toluidine blue-stained bone sections from 6-week-old wild 
type and Grm1crv4/crv4 mice (Figure 4A-B). Here, we observed a moderate enrichment of the bone 
surface and of the trabecular number in the mutated relative to wild type animals. 
We than investigated whether the bone formation could be different in the affected animals (Figure 
4C-D). By 20 weeks, MAR and BFR/BS were both significantly decreased (MAR: 34%; BFR/BS: 
40%) in the femora of Grm1crv4/crv4 compared to those from WT mice. 
 
 
3.2 No evident serum biochemical alterations are present in the Grm1crv4/crv4 mice 
Giving the renal impairment observed in Grm1crv4/crv4 mice [8], we measured a series of circulating 
markers to assess whether systemic effects could account for the skeletal observed abnormalities in 
these mice. Serum analyses of 10 animals of 24-weeks old, sex-matched WT and 10 Grm1crv4/crv4 
mice demonstrated comparable serum levels of Calcium, Phosphorus, Magnesium and 1,25-
dihydroxyvitamin D (Table1) therefore excluding any renal involvement in the observed phenotypic 
changes seen in mutant mice. In addition, serum levels of CTX (Table1) were also comparable 
between WT and Grm1crv4/crv4. Due to renal dysfunction, it might have been possible that serum 
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calcium and 1,25-dihydroxyvitamin D levels were being maintained by elevated PTH, which would 
have skeletal effects. We thus evaluated serum PTH level in 10 WT and 10 Grm1crv4/crv4 mice and no 
statistically significant difference was evidenced (Supplementary figure 3). 
 
 
3.3 Absence of mGlu1 receptor impairs osteoblast differentiation and mineralization in vitro 
To test whether decreased bone formation was directly caused by absence of mGlu1 receptor in 
osteoblasts, we studied the effects of genetic inactivation of mGlu1 receptor on osteoblast 
differentiation and mineralization in vitro. Expression of mGlu1 receptor was confirmed in WT, but 
not in Grm1crv4/crv4 mouse tibia osteoblasts (Supporting information, Supplementary figure 4). 
Osteoblasts obtained from WT and Grm1crv4/crv4 showed similar level of cell survival and proliferation 
rate (Supplementary figure 5), however osteoblasts obtained from mutant mice showed impaired 
mineralization, compared to that observed in WT mouse osteoblasts (Figure 5). Alizarin staining of 
the bone matrix demonstrated that the matrix mineralization was abundant in WT cells while it 
significantly decreased in heterozygous Grm1crv4/+ cells (p<0.05), and was almost completely absent 
in Grm1crv4/crv4 cells (p<0.01) (Figure 5A-B). Accordingly, ALP activity was strongly reduced in 
Grm1crv4/crv4 cells with respect to WT cells (p<0.05) (Figure 3C). 
As collagen is the major matrix component released from osteoblasts, we examined the possibility 
that the quantity of collagen released from Grm1crv4/crv4 mice osteoblasts was reduced with respect to 
the quantity released from WT cells. To this purpose, we first evaluated the SiriusRed staining, which 
specifically stains for collagen regardless of its different isoforms, and did not detect statistically 
significant differences between WT and mutated cells (Figure 5D). We then examined the expression 
of type I collagen, the prevalent component of bone matrix in homeostatic conditions, and found an 
abnormal distribution of type I collagen in the matrix of the mutant as compared to the WT cells 
(Figure 5E). Specifically, osteoblasts derived from Grm1crv4/crv4 mice showed a more scattered 
collagen distribution and less nodular appearance than those obtained from WT animals. 
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Next, to confirm a direct role of mGlu1 receptors in osteoblasts mineralization, we assessed the ability 
of WT osteoblasts to form mineralized matrix in the presence of a selective non-competitive 
antagonist of mGlu1 receptor, CPCCOEt. Matrix mineralization observed in treated mouse WT 
osteoblasts was significantly decreased compared to that seen in the presence of DMSO vehicle 
(p<0.01) and to that of untreated control cells (p<0.05). No statistically significant difference between 
untreated osteoblast control and DMSO-treated osteoblastic cells was observed (Figure 5F-G). 
Furthermore, qRT-PCR revealed a reduction of Collagen type 1 expression in osteoblasts treated with 
CPCCOEt when compared to control cells (p<0.05) (Figure 5H), confirming that mGlu1 receptor 
activity is required for osteoblast homeostasis. Finally, we performed real-time qRT-PCR to evaluate 
whether any differences were present in the expression of collagen type 1, collagen type 3, and the 
osteoblast markers Runx2, Osterix (Sp7) and Osteocalcin (Bglap) at mRNA level (Figure 6). No 
differences were evident except for osteocalcin, which was significantly more expressed in 
osteoblasts of Grm1crv4/crv4 with respect to WT cells. 
 
 
4. Discussion 
While it is well known that glutamate signaling pathways play a major role in the regulation of bone 
formation and dynamics, most studies have focused on ionotropic glutamate receptors. In contrast, 
the relevance of metabotropic glutamate signaling on bone mass regulation has not been investigated. 
In humans, GRM1 inactivating mutations lead to a form of recessive ataxia known as SCAR13 and, 
thus far, all patients reported to be affected by SCAR13 exhibit below the normal range head 
circumference and weight, both at birth and later during infancy; indeed, they show short stature in 
adult age (143-154 cm) [27, 28]. Consistent with these findings, previously we have shown that mice 
in which Grm1 is mutated exhibit cerebellar ataxia, impaired gait, kyphoskolyosis and reduced body 
weight and length compared to WT animals [18]. While the skeletal phenotype could be the direct 
consequence of both neuronal and renal abnormalities seen in these mice, as the bone is equipped 
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with all functional elements of the glutamate signaling, we hypothesized that the GRM1 ablation 
could account for the skeletal phenotype both seen in SCAR13 patients and in Grm1crv4/crv4 mice. To 
test this hypothesis directly, we carried out a detailed characterisation of the skeletal phenotype of the 
Grm1crv4/crv4 mice, specifically directed at testing the contribution that mGlu1 receptor makes to 
osteoblast function. 
In adult female and male Grm1crv4/crv4 mice we mainly observed reduced femoral length, reduced bone 
mineral density and bone surface density when compared to age-matched WT animals. Differences 
in bone mineral and bone surface density were predominantly visible in older mice, suggesting that 
the observed reduction in bone mass is age-related. Accordingly, Grm1crv4/crv4 mice exhibited reduced 
mineralization and bone apposition rates compared to WT mice at 24 weeks of age. 
Unlike in humans, in rodents the longitudinal bone growth continues even after they reach sexual 
maturity [29]. When analysing the morphology of the 12 and 24 weeks bone in Grm1crv4/crv4 and WT 
mice, it was discovered that the growth plate, still very much active in both genotypes at 12 weeks of 
age, at 24 weeks of age in Grm1crv4/crv4 mice the transformation of the growth plate into epiphyseal 
line was already completed while longitudinal bone growth in WT mice has still not ceased. 
Histomorphometry of the tibia from Grm1crv4/crv4 mice indicated a slight increase of bone surface and 
trabecular number compared to WT mice at 6 weeks of age, features suggestive of enhanced bone 
maturation at this age. We performed toluidine blue staining to distinguish in epiphyseal plate 
metachromatic cartilage (blue dark border) from trabecular bone tissue; these data suggest that the 
absence of the mGlu1 receptor causes a premature cessation of the epiphyseal plate in the Grm1crv4/crv4 
mice, with subsequent reduction of bone length in the Grm1crv4/crv4 compared to the WT mice. 
It is well acknowledged that renal damage interferes with bone apposition, resulting in reduction of 
bone density and diameter. In particular, blood and urine sampled from patients with chronic renal 
failure present elevated levels of serum phosphorus and decreased levels of Ca2+ and vitamin D, 
feature markers that indicate the onset of bone dystrophy [30]. Of note, the Grm1crv4/crv4 mice exhibit 
an impaired renal function [8], which is also necessary for the preservation of bone integrity. 
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However, blood analyses performed in the Grm1crv4/crv4 mice indicated normal levels of Ca2+, Pi, 
vitamin D, and Mg compared to WT animals, thus excluding that the skeletal defects shown by the 
Grm1crv4/crv4 mice could be the direct consequence of their renal phenotype. Furthermore, by showing 
similar levels of PTH in mutant and WT mice, we can rule out the influence of this hormone on serum 
calcium and 1,25-dihydroxyvitamin D levels. 
Motor impairment could instead interfere with bone apposition and with the remodelling cycle, and 
could hypothetically account for the observed skeletal phenotype. However, at 21 days of age 
Grm1crv4/crv4 mice already exhibited reduced body weight and length as compared to WT mice (data 
not shown). At this developmental stage, the skeletal tissue cannot be affected by the ataxic 
behaviour. Therefore, a direct role of motor impairment at the origin of the Grm1crv4/crv4 skeletal 
phenotype seems to be unlikely. Indeed, normal serum CTX levels in Grm1crv4/crv4 mice suggest that 
increased bone turnover was not a major cause for the skeletal phenotype of mutant mice. 
Finally, we tested if a decreased activity of bone-forming osteoblasts is responsible for low bone mass 
in Grm1crv4/crv4 mice. 
By in vitro experiments we showed that osteoblasts obtained from Grm1crv4/crv4 mice have the same 
survival and proliferation rate as the WT cells.  Indeed, no differences in number and distribution of 
osteoblast cells were evident at the epiphysis of Grm1crv4/crv4 with respect to WT animals. 
Noteworthy, osteoblasts obtained from mutated mice have a reduced ability to form mineralized 
matrix, when compared to WT cells. In addition, mineralized matrix production by WT osteoblasts 
was impaired when these cells were treated with a mGlu1 receptor specific inhibitor. 
Differences between WT and Grm1crv4/crv4 mice in collagen release from osteoblasts cultures were 
not evident. At RNA level, collagen 1 and 3, the most expressed collagens in the bone matrix, do not 
seem to be more expressed in osteoblasts culture from WT than in Grm1crv4/crv4 mice cells, but  
immunostaining showed differences in collagen type I distribution, and a reduced production of 
collagen I was detected after mGlu1 receptor blockade by CPCCOEt. This first confirms that mGlu1 
receptor activity is required for osteoblast functioning, and suggests that congenital absence of the 
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receptor might induce compensatory mechanisms. Actually, osteoblast cells obtained from 
Grm1crv4/crv4 mice express higher levels of osteocalcin than those obtained from WT animals, 
suggesting a different maturation pattern. Indeed, osteocalcin is a marker of late osteoblast 
differentiation [31], which supports a more rapid maturation of mutated cells, and is in line with the 
observed premature cessation of the epiphyseal plate in the Grm1crv4/crv4 mice in vivo. 
Overall, our studies show that the impaired bone formation in the Grm1crv4/crv4 mice is most likely 
explained by osteoblast malfunction. This finding is in agreement with the findings reported 
previously on the ability of osteoblasts to release and recycle glutamate [16, 17]. 
In the central nervous system, the mGlu1 receptor is primarily coupled to Gq/G11 protein and its 
activation leads to IP3 formation and releases of Ca2+ from intracellular stores (reviewed in [1]). In 
primary culture of rat femoral osteoblasts, it has been suggested that activation mGlu1 receptors is 
linked to an elevation of intracellular Ca2+ levels [4]. Molecular mechanisms regulating intracellular 
calcium homeostasis are fundamental for adequate osteoblast function and differentiation. In the 
nervous system and in other non-neural tissues Group-I mGlu receptors also signal via activation of 
the MAPK and PI3K pathways and ERK1/ERK2 [1], all of which are known important factors 
contributing to osteoblast function, as evidenced by fact that their genetic inactivation inhibits 
osteoblast differentiation [32]. Thus, activation of mGlu1 receptor in bone could also lead to 
activation of these signaling pathways and therefore play a crucial role in bone biology. Impairment 
of this process could contribute to the observed skeletal phenotype in patients affected by GRM1 
inactivating mutations and in Grm1crv4/crv4 mice. 
Finally, mGlu receptors are reported to have a role also in the control of neuroendocrine function 
[33], including modulatory effects on pituitary function [34]. 
Thus, inactivation of mGlu1 receptor may have many different effects in different tissues and organs, 
including bone, nervous system, kidney, which may contribute together to the complex phenotype 
observed in the Grm1crv4 mice. 
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5. Conclusions 
In summary, this work reveals a novel role for metabotropic glutamatergic signaling in bone. We 
show here that in the absence of mGlu1 receptors bone growth is altered, and that osteoblasts mGlu1 
receptors are necessary for skeletal development, longitudinal bone growth and production of normal 
bone matrix. Further experimental work will be necessary to clarify the mechanisms linking mGlu1 
receptors and bone physiology and to clarify to what extent mGlu1 receptors may contribute to bone 
formation and maintenance. 
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Figure 1. Grm1crv4/crv4 mice exhibit reduced body size, shorter femur length and tibia length, reduced 
bone mineral density and reduced surface density compared to WT mice. (A) Images of Grm1crv4/crv4 
(right) and wt (left) adult male mice from the same progeny. (B) Body weight and (C) body length 
are presented as mean±SEM of 20 animals (10 females and 10 males) for each genotype. (D) Femur 
length of females and males, and tibial length of females and males are presented as mean±SD of 
mice of pooled ages (12 – 28 weeks). (E) bone mineral density (BMD) and bone surface density 
(BSD) in males (male mice of pooled ages, 12 – 28 weeks) and in females (female mice of 24 weeks 
of age). Data are presented as mean±SD. p<0.05 (*); p<0.01 (**). 
Figure 2. A. Haematoxylin and eosin (H&E) staining performed on 24 weeks old WT and 
Grm1crv4/crv4 mice. Staining of the hind limbs of 24 weeks old WT mice (right) show that longitudinal 
bone growth is still an on-going process in these mice, with secondary ossification centers present in 
the epiphysis. However, when observing the age-matched Grm1crv4/crv4 mice (left) it was noted that 
the growth plate fused ceasing the longitudinal bone growth in these mice, there do not appear to be 
any secondary ossification centers present in the epiphysis of these animals. Images of the growth 
plate/epiphyseal line were taken at x20 magnification and the scale bars represent 1mm. DC, 
differentiated chondrocytes; OM, ossified matrix, PC, proliferative chondrocytes, SOC, secondary 
ossification centres. B. Labeling of ALP and TRAP in WT and Grm1crv4/crv4 epiphysis bone mice by 
enzymatic histochemistry. Arrows in the left panel indicate ALP-positive cells, osteoblasts. Arrows 
in the right panel indicate TRACP-positive cells, osteoclasts. The inset images were taken at 40X 
magnification and the scale bars represent 50μm. 
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Figure 3. Osteoblasts and osteoclasts in bone tissue of WT and Grm1crv4/crv4 mice A-B. 
Immunofluorescence shows expression of the mGlu1 receptor (green) and Runx2 (red), a marker for 
osteoblasts, in the bone diaphysis of a wild-type (A) and of a Grm1crv4/crv4 (B) mouse. Runx2-
expressing osteoblasts are observable in both WT and mutated tissues (arrows). Green-red double 
stained cells, indicating the presence of mGlu1 receptor-expressing osteoblasts, are observable in the 
WT tissue and absent in the mutated mouse bone tissue. C. Number of osteoblasts per bone surface 
in WT and mutated bone tissues are presented as mean±SD. D-F. Immunofluorescence shows 
expression of the mGlu1 receptor (green) and CD68 (red), a marker for osteoclasts, in the bone 
epiphysis of a WT (D-E) and of a Grm1crv4/crv4 (F) mouse. CD68-expressing osteoclasts are observable 
in both WT and mutated tissues (arrows). Few green-red double stained cells, indicating the presence 
of mGlu1 receptor-expressing osteoclasts, are observable in the WT tissue and absent in the mutated 
mouse bone tissue. G. Number of osteoclasts per bone surface in WT and mutated bone tissues are 
presented as mean±SD. The inset images were taken at 50X magnification and the scale bars represent 
50µm. 
Figure 4. Static and dynamic histomorphometry of WT and Grm1crv4/crv4 bone tissues. (A) Toluidine 
blue-stained sections from tibiae of 6-week-old female mice. Scale bar, 200 μm. (B) Analysis of 
relative bone volume (BV/TV) and trabecular number (Tb.N) is shown. All values are mean ± SEM 
from three mice per group at 6 weeks of age. (C) Representative calcein-labeled sections of femur 
bone from WT and Grm1crv4/crv4 male mice. Images were taken at x200 magnification. (D) Mineral 
apposition rate (MAR) and bone formation rate (BFR/BS) calculated from calcein double labelling 
are shown in WT and Grm1crv4/crv4 mice. Bone formation rate is the amount of mineralised bone 
formed per unit of time per unit of bone surface. All values are mean ± SEM from three mice per 
group at 24 weeks of age. p<0.05 (*) ; p<0.01 (**). 
Figure 5. Mineralization matrix defects are seen in mice lacking mGlu1 receptor. A. Light 
microscopy images of alizarin red staining of primary osteoblasts obtained from WT, Grm1crv4/+ and 
Grm1crv4/crv4 mice and (B) quantification of alizarin extracted from primary cells. C. ALP activity is 
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reduced in Grm1crv4/crv4 mice with respect to WT mice. D. Content of collagen measured by SiriusRed 
assay and normalized by Janus Green. E. Collagen I expression in primary osteoblasts obtained from 
WT and Grm1crv4/crv4 mice. Scale bar 50 µm. Magnification: 40X. F. Light microscopy images of 
alizarin red staining of primary osteoblasts obtained from WT mice, cultured with CPCCOEt, DMSO 
and control (CTRL) and (G) quantification of alizarin red extracted from primary cells. H. Collagen 
I mRNA expression of primary osteoblasts of WT mouse treated with CPCCOEt or DMSO (vehicle 
control). Bars are means ± SD. p<0.05 (*); p<0.01 (**). 
Figure 6. Results of real-time qRT-PCR obtained from osteoblast cultures. 
 
 
